by Bruce Sylvester: Lenvatinib treatment has resulted in significant improvement in progression-free survival among patients with advanced radioiodine-refractory thyroid cancer, researchers from a Phase III trial reported in… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
